Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, today presented positive, final data from the ...

Experts that The Cool Down has spoken to suggest that foods and drinks with aspartame can be less unhealthy than those with ...

A new study in the peer-reviewed Journal of Interferon & Cytokine Research (JICR) showed that a specific retinoic ...

Metabolic dysfunction-associated steatohepatitis (MASH) significantly increases the risk of liver cirrhosis and ...

Researchers assessed the prognostic significance of older age and comorbidity burden on overall survival in patients with hepatocellular carcinoma.

Amezalpat received fast track designation from the FDA for the treatment of patients with hepatocellular carcinoma.

Fast Track Designation highlights potential of amezalpat to address unmet need for patients with HCC. Amezalpat builds momentum with both Fast Track and Orphan Drug Designations.

Despite the limited OS events, the trend toward better OS benefit was observed with TACE combined camrelizumab and rivoceranib. The safety profile for the combination of TACE+camrelizumab ...

For patients with hepatocellular carcinoma (HCC) treated with conventional transarterial ... Currently, deep learning is a popular trend, but undoubtedly, new trends will emerge in the future. Despite ...

Cancer cases in Jammu and Kashmir have increased by 50 percent at Paras Health Srinagar from September 2023 to January 2025, highlighting the growing need for early detection, awareness, and improved ...